# Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

> **NCT00651729** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 279 (actual)

## Conditions studied

- Stroke
- Muscle Spasticity

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type A

## Key facts

- **NCT ID:** NCT00651729
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2008-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651729, "Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00651729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*